Brokers Issue Forecasts for Day One Biopharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Investment analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Day One Biopharmaceuticals in a research note issued on Wednesday, April 24th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($2.79) per share for the year, up from their previous estimate of ($2.80). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ FY2025 earnings at ($2.43) EPS, FY2026 earnings at ($1.34) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $1.87 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Several other research firms have also commented on DAWN. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. JPMorgan Chase & Co. increased their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Monday, April 22nd. Needham & Company LLC lifted their price target on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Day One Biopharmaceuticals Price Performance

Shares of DAWN stock opened at $14.92 on Friday. The stock’s 50-day moving average is $15.22 and its 200 day moving average is $13.81. Day One Biopharmaceuticals has a 1-year low of $9.67 and a 1-year high of $17.85. The company has a market cap of $1.30 billion, a P/E ratio of -6.27 and a beta of -1.48.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Hennion & Walsh Asset Management Inc. lifted its holdings in Day One Biopharmaceuticals by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after acquiring an additional 1,445 shares during the period. Fisher Asset Management LLC lifted its stake in shares of Day One Biopharmaceuticals by 89.0% in the 4th quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock valued at $999,000 after purchasing an additional 32,238 shares during the period. Wellington Management Group LLP boosted its holdings in Day One Biopharmaceuticals by 77.7% during the fourth quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock worth $3,051,000 after buying an additional 91,393 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Day One Biopharmaceuticals by 28.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after buying an additional 472,654 shares during the period. Finally, Quintet Private Bank Europe S.A. raised its position in shares of Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total transaction of $322,200.00. Following the sale, the insider now owns 1,224,662 shares in the company, valued at approximately $19,729,304.82. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider Samuel C. Blackman sold 20,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total transaction of $322,200.00. Following the completion of the sale, the insider now owns 1,224,662 shares of the company’s stock, valued at $19,729,304.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Adam Dubow sold 3,242 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $49,440.50. Following the completion of the transaction, the general counsel now owns 16,585 shares in the company, valued at approximately $252,921.25. The disclosure for this sale can be found here. Insiders have sold a total of 55,781 shares of company stock valued at $883,160 in the last ninety days. Company insiders own 8.40% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.